Arya Jain’s Post

Check out this article from Pharmaceutical Executive. The global radiopharmaceutical market is on track to grow from $9.07 billion in 2023 to an impressive $26.51 billion by 2031, fueled by advancements in diagnostic and therapeutic applications for conditions like cancer and Alzheimer’s disease. Established markets in North America continue to benefit from robust infrastructure and innovation in theranostics and AI-driven personalized medicine. This evolution is a game-changer in healthcare, promising enhanced treatment precision and expanded patient access worldwide. Read the full article: https://bit.ly/3O14fcZ #Radiopharmaceuticals #HealthcareInnovation #Theranostics

The global best-selling drugs rankings can reflect the current popular research areas and types of medications to some extent. According to the analysis of the 2024 Q1 global best-selling drugs rankings data, biopharmaceuticals have taken a dominant position, with oncology, autoimmune diseases, and chronic diseases being the three major hot fields at present (Table 1: Top 20 Global Best-Selling Drugs in Q1 2024 (in Billion USD)). #APIs #Medical #Rawmaterials #Pharma #Medicine #Pharmaceutical

Pharma service providers, did you know that in the last 24 hours, over 35 pharma and biotech companies in North America have announced upcoming Phase 1, 2, and 3 studies? 🚀 Take NeuroBo Pharmaceuticals as an example; with a lean team of 10 and over $85M in funding this year, they are advancing towards a Phase 2 study targeting cardiomyopathy associated with DMD and cystic fibrosis. Stay ahead and turn these actionable insights into opportunities! DM or email me at amarpreet.singh@zymewire.com to explore how Zymewire can help you stay proactive and capture these insights.

Dr. Reddy’s has introduced #Toripalimab in #India, marking it as the first immuno-#oncology therapy approved for RM-NPC https://lnkd.in/gf9jSD5j #Pharma #pharmaceutical #healthcare #news #media #medicine #Bharat #India #CDSCO #NarendraModi #AyushmanBharat #breaking #DrReddys

✨ Drug Price Hikes Under Scrutiny ✨ The U.S. drug pricing watchdog ICER recently flagged five major pharmaceutical companies for "unjustified price increases" on several key medications. These hikes, which lack evidence of clinical improvement, are driving up costs for patients and the healthcare system. Some of the notable drugs called out include: • AbbVie's Humira – a critical treatment for autoimmune conditions. • Bayer's Nubeqa – a prostate cancer therapy. ICER’s report highlights the growing debate around balancing innovation with affordability. Patients and healthcare stakeholders are calling for greater transparency and accountability when it comes to pricing decisions. As the industry faces increasing scrutiny, the question remains: How can we ensure fair access to life-saving medications while fostering innovation? At MedMind, we continue to track these critical developments and explore how policy, innovation, and pricing align to impact healthcare delivery. https://lnkd.in/gS6ThXhe #DrugPricing #PharmaNews #HealthcareInnovation #MedMind #PatientAccess #LifeSciences

Radiodermatitis Market Insights: Growth and Future Prospects The global radiodermatitis market is on a growth trajectory, driven by rising cancer rates and advancements in radiation therapy. With a projected CAGR of 5.8% from 2023 to 2030, the market offers significant opportunities for pharmaceutical companies, particularly in emerging markets. As awareness of radiodermatitis management increases, so does the demand for effective treatments. Companies focusing on innovative product development and strategic partnerships are likely to gain a competitive edge in this expanding market. Explore more insights in our latest report on the global radiodermatitis market:https://lnkd.in/dvhTdYPt #Radiodermatitis #CancerTreatment #HealthcareInnovation #MarketResearch

Global #Pharmaceutical Landscape Sees Surge in Novel Active Substances The pharmaceutical industry witnessed a significant development in 2023 with the launch of 69 𝐍𝐨𝐯𝐞𝐥 𝐀𝐜𝐭𝐢𝐯𝐞 𝐒𝐮𝐛𝐬𝐭𝐚𝐧𝐜𝐞𝐬 (𝐍𝐀𝐒𝐬), marking a noteworthy 10% increase from the previous year. This increase not only highlights the sector's recovery post-COVID-19 but also reflects a return to the robust innovation levels seen before the pandemic. The rise in NAS launches signals continued investment in research and development, particularly in high-impact areas like cancer, neurological disorders, and infectious diseases, and is expected to drive future innovations, improving #globalhealth outcomes. #covid19 #drugdevelopment #iqvia #insights10

Unlock the potential of high-value biologics with our large-volume RTU cartridges! New treating therapies such as autoimmune diseases, Parkinson’s, and cancer could require complex delivery profiles, large volumes (>3mL), or high-viscosity drugs. Large-Volume RTU Cartridges combined with on-body delivery systems are used to enable such complex subcutaneous injections in home-care setting. With sizes ranging from 5ml to 20ml, we offer the widest range of validated cartridge formats and related rubber components, simplifying the selection process for pharmaceutical companies. This flexibility allows for seamless integration into various delivery systems, from external infusion pumps to on-body delivery systems. Discover the advantages of our EZ-fill® cartridges and see how they can enhance an optimal delivery of your high-value biologics. Read more about our innovative solutions: https://lnkd.in/dgJ_VZPM #StevanatoGroup #IntegratedSolutionsProvider #RTU #Cartridges

The 𝐄𝐮𝐫𝐨𝐩𝐞 #oncology #biosimilars market is driven by the increasing incidence of cancer #worldwide boosts the demand for cost-effective #treatment options like biosimilars, which are similar to but less expensive than original #biologic drugs. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞: https://lnkd.in/gyrqmVV6 Sandoz, Amgen, Celltrion Healthcare UK Ltd, Samsung Bioepis, Apotex Inc., Auxilium Pharmaceuticals, Inc. (now Endo International)., BIOCAD, Glenmark Pharmaceuticals, AUROBINDO PHARMA LTD, Cipla, Zydus Group, GSK, Wohlfahrtsstiftung der F. Hoffmann-La Roche AG #marketanalysis #marketgrowth #marketdata #marketsize #marketshare #markettrends #marketreport #marketoutlook #marketoverview #drivers #marketresearchreport #marketsegmentation #marketsummary #restraints #researchanddevelopment #researchmethods #researchreport #marketdemand

In this week's pharmaceutical industry news, market growth forecasts, significant acquisitions, and investments come to the fore. We have compiled the most prominent developments for you. Enjoy your reading! 1. A report by the Business Research Company predicts that the small-molecule injectable drugs market will value $355.14 billion in 2028. https://lnkd.in/dJ2RXY9j 2. Research suggests that the process spectroscopy market will gain a compound annual growth rate (CAGR) of 5.33 percent by 2033. https://lnkd.in/dCGtP9MN 3. #GSK enhances oligonucleotide capabilities with $50m Elsie acquisition. https://lnkd.in/dTZQqaU7 4. #EliLilly gains rights to QurAlis’ neurodegenerative disease therapy in deal worth over $620m. https://lnkd.in/epGDC4mA 5. #AstraZeneca immunotherapy could boost lung cancer survival https://lnkd.in/dgNXBwHY #pharmanews #pharmaindustry #fitminds #strategyconsulting